Semaglutide (Brand)

Overview

Semaglutide is a GLP-1 receptor agonist, a class of medication that imitates glucagon-like peptide-1 — a hormone the gut releases in response to food. It was first approved for type 2 diabetes and later for chronic weight management, and it has become one of the most widely studied compounds in metabolic medicine.

Unlike many peptides discussed in research circles, semaglutide is a fully approved prescription drug backed by large randomized clinical trials. It is sold by Novo Nordisk under the brand names Ozempic and Rybelsus (for diabetes) and Wegovy (for weight management).

Because it is a regulated medication rather than a research chemical, semaglutide is prescribed and monitored by clinicians, and its efficacy and safety have been characterized in trial programs enrolling tens of thousands of participants.

How it works

GLP-1 is an incretin hormone involved in regulating blood sugar and appetite. Semaglutide activates the GLP-1 receptor, which prompts the pancreas to release insulin when glucose is elevated and reduces the release of glucagon. This helps lower blood sugar in people with type 2 diabetes.

GLP-1 receptors are also present in areas of the brain that govern appetite and satiety. By acting on these pathways and by slowing the rate at which the stomach empties, semaglutide tends to reduce hunger and increase the feeling of fullness. These combined effects are thought to underlie the weight-loss seen in clinical studies.

Reported benefits

• Studied for improved blood-sugar control in type 2 diabetes
• Studied for meaningful weight reduction in adults with overweight or obesity (STEP trial program)
• Associated with reduced risk of major cardiovascular events in a large trial of people with established heart disease and overweight or obesity (SELECT trial)
• Commonly reported reductions in appetite and food intake

These are outcomes observed in clinical research and depend on the individual, the indication, and clinical supervision.

Considerations & side effects

The most commonly reported side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — which are often most noticeable when treatment begins or when the dose is increased. Less common but more serious concerns discussed in the prescribing information include pancreatitis, gallbladder problems, and, in animal studies, thyroid C-cell tumors.

Semaglutide carries a boxed warning regarding thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is a prescription medication and is not a substitute for evaluation and ongoing monitoring by a qualified clinician, who can assess suitability and manage dosing.